OA13303A - Sustained-release tablet composition of pramipexole. - Google Patents

Sustained-release tablet composition of pramipexole. Download PDF

Info

Publication number: OA13303A
Authority: OA; OAPI
Prior art keywords: composition; tablet; pramipexole; coating; release
Prior art date: 2002-07-25

Application number

OA1200500016A

Other languages

English (en)

Inventor

Gregory E Amidon

Loksidh D Ganorkar

John M Heimlich

Ernest J Lee

Robert M Noack

Joseph P Reo

Connie J Skoug

Original Assignee

Pharmacia Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-07-25

Filing date

2003-07-25

Publication date

2007-04-13

2003-07-25 Application filed by Pharmacia Corp filed Critical Pharmacia Corp

2007-04-13 Publication of OA13303A publication Critical patent/OA13303A/en

Links

FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical group C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 title claims abstract description 42
229960003089 pramipexole Drugs 0.000 title claims abstract description 35
239000000203 mixture Substances 0.000 title claims description 61
239000007939 sustained release tablet Substances 0.000 title description 17
229920002472 Starch Polymers 0.000 claims abstract description 41
235000019698 starch Nutrition 0.000 claims abstract description 41
239000008107 starch Substances 0.000 claims abstract description 37
239000007787 solid Substances 0.000 claims abstract description 27
229920001477 hydrophilic polymer Polymers 0.000 claims abstract description 15
238000013268 sustained release Methods 0.000 claims abstract description 15
239000012730 sustained-release form Substances 0.000 claims abstract description 15
239000011159 matrix material Substances 0.000 claims abstract description 13
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
239000011248 coating agent Substances 0.000 claims description 52
238000000576 coating method Methods 0.000 claims description 52
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 39
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 39
229920000881 Modified starch Polymers 0.000 claims description 33
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 21
229960002652 pramipexole dihydrochloride Drugs 0.000 claims description 17
VQMNWIMYFHHFMC-UHFFFAOYSA-N tert-butyl 4-hydroxyindole-1-carboxylate Chemical group C1=CC=C2N(C(=O)OC(C)(C)C)C=CC2=C1O VQMNWIMYFHHFMC-UHFFFAOYSA-N 0.000 claims description 17
229950010601 pramipexole dihydrochloride monohydrate Drugs 0.000 claims description 13
239000001856 Ethyl cellulose Substances 0.000 claims description 12
229920001249 ethyl cellulose Polymers 0.000 claims description 12
235000019325 ethyl cellulose Nutrition 0.000 claims description 12
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
229940096895 Dopamine D2 receptor agonist Drugs 0.000 claims description 3
229920002125 Sokalan® Polymers 0.000 claims description 3
201000010099 disease Diseases 0.000 claims description 3
239000002288 dopamine 2 receptor stimulating agent Substances 0.000 claims description 3
229920000609 methyl cellulose Polymers 0.000 claims description 3
239000001923 methylcellulose Substances 0.000 claims description 3
235000010981 methylcellulose Nutrition 0.000 claims description 3
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
229960001631 carbomer Drugs 0.000 claims description 2
150000003839 salts Chemical class 0.000 abstract description 4
239000003826 tablet Substances 0.000 description 116
239000000463 material Substances 0.000 description 21
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 16
238000004090 dissolution Methods 0.000 description 16
238000012360 testing method Methods 0.000 description 14
238000007906 compression Methods 0.000 description 13
230000006835 compression Effects 0.000 description 13
239000003814 drug Substances 0.000 description 13
238000000338 in vitro Methods 0.000 description 13
238000001727 in vivo Methods 0.000 description 13
238000010998 test method Methods 0.000 description 12
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 11
238000000034 method Methods 0.000 description 11
238000011282 treatment Methods 0.000 description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
239000003795 chemical substances by application Substances 0.000 description 10
229940079593 drug Drugs 0.000 description 10
229920000642 polymer Polymers 0.000 description 10
238000010521 absorption reaction Methods 0.000 description 8
239000000377 silicon dioxide Substances 0.000 description 8
235000012239 silicon dioxide Nutrition 0.000 description 8
238000004458 analytical method Methods 0.000 description 7
239000002552 dosage form Substances 0.000 description 7
238000009472 formulation Methods 0.000 description 7
239000012729 immediate-release (IR) formulation Substances 0.000 description 7
230000002411 adverse Effects 0.000 description 6
238000002648 combination therapy Methods 0.000 description 6
208000035475 disorder Diseases 0.000 description 6
230000001965 increasing effect Effects 0.000 description 6
239000000314 lubricant Substances 0.000 description 6
239000000651 prodrug Substances 0.000 description 6
229940002612 prodrug Drugs 0.000 description 6
229940101972 mirapex Drugs 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
239000007916 tablet composition Substances 0.000 description 5
230000004584 weight gain Effects 0.000 description 5
235000019786 weight gain Nutrition 0.000 description 5
230000000694 effects Effects 0.000 description 4
238000013265 extended release Methods 0.000 description 4
239000010410 layer Substances 0.000 description 4
VOJRMYBBPKNLLI-ORHWHDKWSA-N sumanirole maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@H](C1)NC)C2=CC=CC3=C2N1C(=O)N3 VOJRMYBBPKNLLI-ORHWHDKWSA-N 0.000 description 4
206010053317 Hydrophobia Diseases 0.000 description 3
208000001089 Multiple system atrophy Diseases 0.000 description 3
206010031127 Orthostatic hypotension Diseases 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
239000011247 coating layer Substances 0.000 description 3
230000001747 exhibiting effect Effects 0.000 description 3
239000012530 fluid Substances 0.000 description 3
239000013563 matrix tablet Substances 0.000 description 3
239000000843 powder Substances 0.000 description 3
229940124597 therapeutic agent Drugs 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
208000018737 Parkinson disease Diseases 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
239000008186 active pharmaceutical agent Substances 0.000 description 2
239000012736 aqueous medium Substances 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
239000007891 compressed tablet Substances 0.000 description 2
238000005336 cracking Methods 0.000 description 2
230000007547 defect Effects 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000004014 plasticizer Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
-1 polymorphe Chemical class 0.000 description 2
APVQOOKHDZVJEX-QTPLPEIMSA-N pramipexole hydrochloride Chemical compound O.Cl.Cl.C1[C@@H](NCCC)CCC2=C1SC(N)=N2 APVQOOKHDZVJEX-QTPLPEIMSA-N 0.000 description 2
238000001812 pycnometry Methods 0.000 description 2
238000005070 sampling Methods 0.000 description 2
238000009097 single-agent therapy Methods 0.000 description 2
230000009747 swallowing Effects 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
229920003176 water-insoluble polymer Polymers 0.000 description 2
BIIBYWQGRFWQKM-JVVROLKMSA-N (2S)-N-[4-(cyclopropylamino)-3,4-dioxo-1-[(3S)-2-oxopyrrolidin-3-yl]butan-2-yl]-2-[[(E)-3-(2,4-dichlorophenyl)prop-2-enoyl]amino]-4,4-dimethylpentanamide Chemical compound CC(C)(C)C[C@@H](C(NC(C[C@H](CCN1)C1=O)C(C(NC1CC1)=O)=O)=O)NC(/C=C/C(C=CC(Cl)=C1)=C1Cl)=O BIIBYWQGRFWQKM-JVVROLKMSA-N 0.000 description 1
ZAMLGGRVTAXBHI-UHFFFAOYSA-N 3-(4-bromophenyl)-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NC(CC(O)=O)C1=CC=C(Br)C=C1 ZAMLGGRVTAXBHI-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
229920000945 Amylopectin Polymers 0.000 description 1
229920000856 Amylose Polymers 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
206010013710 Drug interaction Diseases 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
229920003091 Methocel™ Polymers 0.000 description 1
FASDKYOPVNHBLU-UHFFFAOYSA-N N6-Propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine Chemical compound C1C(NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-UHFFFAOYSA-N 0.000 description 1
240000007594 Oryza sativa Species 0.000 description 1
235000007164 Oryza sativa Nutrition 0.000 description 1
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
241000209140 Triticum Species 0.000 description 1
235000021307 Triticum Nutrition 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
229940081735 acetylcellulose Drugs 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
239000002585 base Substances 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
238000010241 blood sampling Methods 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
235000019519 canola oil Nutrition 0.000 description 1
239000000828 canola oil Substances 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
229940105329 carboxymethylcellulose Drugs 0.000 description 1
229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
229950008138 carmellose Drugs 0.000 description 1
239000000679 carrageenan Substances 0.000 description 1
235000010418 carrageenan Nutrition 0.000 description 1
229920001525 carrageenan Polymers 0.000 description 1
229940113118 carrageenan Drugs 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
239000011436 cob Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
239000012738 dissolution medium Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
229960003638 dopamine Drugs 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000012458 free base Substances 0.000 description 1
FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
229940046813 glyceryl palmitostearate Drugs 0.000 description 1
238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
239000008172 hydrogenated vegetable oil Substances 0.000 description 1
125000004356 hydroxy functional group Chemical group O* 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
238000007689 inspection Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
206010027175 memory impairment Diseases 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
150000004682 monohydrates Chemical class 0.000 description 1
231100001079 no serious adverse effect Toxicity 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
XULSCZPZVQIMFM-IPZQJPLYSA-N odevixibat Chemical compound C12=CC(SC)=C(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(O)=O)C=3C=CC(O)=CC=3)C=C2S(=O)(=O)NC(CCCC)(CCCC)CN1C1=CC=CC=C1 XULSCZPZVQIMFM-IPZQJPLYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229960000502 poloxamer Drugs 0.000 description 1
239000004584 polyacrylic acid Substances 0.000 description 1
229920002689 polyvinyl acetate Polymers 0.000 description 1
239000011118 polyvinyl acetate Substances 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
235000019422 polyvinyl alcohol Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000011148 porous material Substances 0.000 description 1
229920003124 powdered cellulose Polymers 0.000 description 1
235000019814 powdered cellulose Nutrition 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
235000009566 rice Nutrition 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000015424 sodium Nutrition 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
229960003885 sodium benzoate Drugs 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
241000894007 species Species 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000003756 stirring Methods 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
229950011111 sumanirole Drugs 0.000 description 1
RKZSNTNMEFVBDT-MRVPVSSYSA-N sumanirole Chemical compound C([C@H](C1)NC)C2=CC=CC3=C2N1C(=O)N3 RKZSNTNMEFVBDT-MRVPVSSYSA-N 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
235000019731 tricalcium phosphate Nutrition 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)

OA1200500016A 2002-07-25 2003-07-25 Sustained-release tablet composition of pramipexole. OA13303A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US39842702P	2002-07-25	2002-07-25
US39844702P	2002-07-25	2002-07-25
US47951303P	2003-06-18	2003-06-18

Publications (1)

Publication Number	Publication Date
OA13303A true OA13303A (en)	2007-04-13

Family

ID=31192087

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200500016A OA13303A (en)	2002-07-25	2003-07-25	Sustained-release tablet composition of pramipexole.

Country Status (40)

Country	Link
US (2)	US20050226926A1 (fr)
EP (2)	EP1531814B1 (fr)
JP (1)	JP4700963B2 (fr)
KR (1)	KR100712832B1 (fr)
CN (1)	CN1313092C (fr)
AP (1)	AP2201A (fr)
AR (1)	AR040681A1 (fr)
AT (1)	ATE406162T1 (fr)
AU (1)	AU2003261241B2 (fr)
BR (1)	BR0312960A (fr)
CA (1)	CA2492854C (fr)
CR (1)	CR7661A (fr)
CU (1)	CU23440B7 (fr)
CY (1)	CY1110408T1 (fr)
DE (1)	DE60323235D1 (fr)
DK (1)	DK1531814T3 (fr)
EA (2)	EA200702187A1 (fr)
EC (1)	ECSP055568A (fr)
ES (1)	ES2310673T3 (fr)
GE (1)	GEP20074048B (fr)
HR (1)	HRP20041235B1 (fr)
IL (1)	IL166078A0 (fr)
IS (1)	IS7623A (fr)
MA (1)	MA27328A1 (fr)
ME (1)	MEP52308A (fr)
MX (1)	MXPA05001054A (fr)
MY (1)	MY138846A (fr)
NO (1)	NO334298B1 (fr)
NZ (1)	NZ537790A (fr)
OA (1)	OA13303A (fr)
PA (1)	PA8578301A1 (fr)
PE (1)	PE20040130A1 (fr)
PL (1)	PL215587B1 (fr)
PT (1)	PT1531814E (fr)
RS (1)	RS51719B (fr)
SI (1)	SI1531814T1 (fr)
TW (1)	TWI347849B (fr)
UY (1)	UY27912A1 (fr)
WO (1)	WO2004010997A1 (fr)
ZA (1)	ZA200500439B (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20060281797A1 (en) *	2001-12-11	2006-12-14	University Of Virginia Patent Foundation	Neurorestoration with R(+) Pramipexole
ES2432527T3 (es) *	2001-12-11	2013-12-04	University Of Virginia Patent Foundation	Uso de pramipexol para tratar la esclerosis lateral amiotrófica
US20050226926A1 (en)	2002-07-25	2005-10-13	Pfizer Inc	Sustained-release tablet composition of pramipexole
PA8578501A1 (es) *	2002-07-25	2005-02-04	Pharmacia Corp	Forma de dosificacion una vez al dia de pramipexol
US20070196481A1 (en) *	2002-07-25	2007-08-23	Amidon Gregory E	Sustained-release tablet composition
US9101155B2 (en)	2003-07-11	2015-08-11	Asahi Kasei Chemicals Corporation	Functional starch powder
UA93608C2 (ru) *	2004-08-13	2011-02-25	Берингер Ингельхайм Интернациональ Гмбх	композициЯ таблетки пролонгированного высвобождения, которая содержит прамипексол или его фармацевтически приемлемую соль, СПОСОБ EE ИЗГОТОВЛЕНИЯ И EE ПРИМЕНЕНИЕ
CN101022788B (zh) *	2004-08-13	2010-11-10	贝林格尔·英格海姆国际有限公司	包含普拉克索或其可药用盐的延长释放小球制剂、其制备方法及其用途
DE602004022205D1 (de) *	2004-09-09	2009-09-03	Psicofarma S A De C V	Pharmazeutische zusammensetzung für die verzögerte freisetzung von hydralazin und ihre verwendung als unterstützung zur krebstherapie
EP1731514A1 (fr) *	2005-06-02	2006-12-13	Sandoz AG	Méthode de préparation du pramipexole
ATE444750T1 (de) *	2005-08-15	2009-10-15	Univ Virginia	Neurorestauration mit r(+) pramipexol
WO2007090883A1 (fr) *	2006-02-10	2007-08-16	Boehringer Ingelheim International Gmbh	Formulation à libération prolongée
EP1988875A2 (fr) *	2006-02-10	2008-11-12	Boehringer Ingelheim International GmbH	Formulation a liberation modifiee
WO2007090882A2 (fr) *	2006-02-10	2007-08-16	Boehringer Ingelheim International Gmbh	Compositions pharmaceutiques
US8518926B2 (en)	2006-04-10	2013-08-27	Knopp Neurosciences, Inc.	Compositions and methods of using (R)-pramipexole
US20070259930A1 (en) *	2006-04-10	2007-11-08	Knopp Neurosciences, Inc.	Compositions and methods of using r(+) pramipexole
ATE537826T1 (de)	2006-05-16	2012-01-15	Knopp Neurosciences Inc	Zusammensetzungen aus r(+)- und s(-)-pramipexol sowie verfahren zu ihrer anwendung
WO2008001204A2 (fr) *	2006-06-29	2008-01-03	Antares Pharma Ipl Ag	Compositions transdermiques de pramipexole présentant des propriétés de perméation améliorées
US8524695B2 (en) *	2006-12-14	2013-09-03	Knopp Neurosciences, Inc.	Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
JP2010521496A (ja)	2007-03-14	2010-06-24	ノップニューロサイエンシーズ、インク．	キラル精製置換ベンゾチアゾールジアミンの合成
US20100092554A1 (en) *	2007-04-24	2010-04-15	Boehringer Ingelheim International Gmbh	Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
WO2008150741A1 (fr) *	2007-06-04	2008-12-11	Drugtech Corporation	Compositions d'agoniste de dopamine à libération contrôlée
EP2291178A4 (fr) *	2008-06-09	2013-07-24	Supernus Pharmaceuticals Inc	Formulations à libération contrôlée de pramipexole
US20110190356A1 (en)	2008-08-19	2011-08-04	Knopp Neurosciences Inc.	Compositions and Methods of Using (R)- Pramipexole
AU2010262970A1 (en) *	2009-06-19	2012-01-12	Knopp Neurosciences, Inc.	Compositions and methods for treating amyotrophic lateral sclerosis
EP2448411A4 (fr) *	2009-07-02	2012-11-28	Supernus Pharmaceuticals Inc	Procédé de traitement d'un trouble neurologique
WO2011037976A2 (fr) *	2009-09-22	2011-03-31	Dr. Reddy's Laboratories Limited	Formulations pharmaceutiques de pramipexole
EP2525786A2 (fr)	2010-01-18	2012-11-28	Synthon BV	Comprimés à libération prolongée de pramipexole
TR201001862A1 (tr)	2010-03-11	2011-10-21	Sanovel �La� San.Ve T�C.A.�.	Kontrollü salım gerçekleştiren pramipeksol formülasyonları.
JP2013526601A (ja)	2010-05-24	2013-06-24	ルピン・リミテッド	プラミペキソールの徐放性製剤
KR101307334B1 (ko) *	2010-07-02	2013-09-12	주식회사 바이오파마티스	프라미펙솔 또는 이의 약학적으로 허용되는 염을 포함하는 안정성이 개선된 서방형 약학 조성물
WO2013034173A1 (fr)	2011-09-06	2013-03-14	Synthon Bv	Comprimés à libération prolongée de pramipexole
WO2013096816A1 (fr)	2011-12-22	2013-06-27	Biogen Idec Ma Inc.	Synthèse améliorée de composés substitués par amine de 4,5,6,7-tétrahydrobenzothiazole
EP2732812A1 (fr)	2012-11-15	2014-05-21	Aristo Pharma GmbH	Comprimé de pramipexol à libération prolongée
US9662313B2 (en)	2013-02-28	2017-05-30	Knopp Biosciences Llc	Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9468630B2 (en)	2013-07-12	2016-10-18	Knopp Biosciences Llc	Compositions and methods for treating conditions related to increased eosinophils
PL3019167T3 (pl)	2013-07-12	2021-06-14	Knopp Biosciences Llc	Leczenie podwyższonych poziomów eozynofili i/lub bazofili
EP3038467B1 (fr)	2013-08-13	2020-07-29	Knopp Biosciences LLC	Compositions et méthodes de traitement de troubles des cellules plasmatiques et de troubles prolymphocytaires à cellules b
DK3033081T3 (da)	2013-08-13	2021-05-31	Knopp Biosciences Llc	Sammensætninger og fremgangsmåder til behandling af kronisk urticaria
CN103520128B (zh)	2013-10-12	2018-08-21	石家庄杏林锐步医药科技股份有限公司	一种普拉克索的缓释片剂、制备方法及其用途
IL312486B2 (en)	2017-04-10	2025-05-01	Chase Therapeutics Corp	NK1 antagonist combination and method for treating synucleinopathies
CN110719778B (zh)	2017-04-24	2024-06-18	才思治疗公司	用于治疗抑郁的组合物和方法
CA3104811C (fr)	2017-06-30	2024-05-28	Chase Therapeutics Corporation	Composition comprenant du pramipexole et des antagonistes nk1 pour traiter la depression
CN109316466B (zh) *	2017-07-31	2022-04-05	深圳翰宇药业股份有限公司	一种盐酸普拉克索缓释制剂及其制备方法
US11234961B2 (en)	2017-08-17	2022-02-01	Zi-Qiang Gu	Pamoate salt of monoamine anti-Parkinson's agents, method of preparation and use thereof
CN113876729B (zh) *	2021-11-11	2023-05-30	南通联亚药业股份有限公司	一种盐酸普拉克索缓释片剂及其制备方法

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US15735A (en) *		1856-09-16		Improvement in harvesters
US2887440A (en) *	1957-08-12	1959-05-19	Dow Chemical Co	Enteric coating
US3845770A (en)	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
JPS58403B2 (ja)	1975-07-24	1983-01-06	武田薬品工業株式会社	Ｌ− アスコルビンサンセイザイノセイゾウホウ
US4140755A (en)	1976-02-13	1979-02-20	Hoffmann-La Roche Inc.	Sustained release tablet formulations
CH649215A5 (de)	1981-04-29	1985-05-15	Hoffmann La Roche	Pharmazeutische praeparate.
SE8103843L (sv)	1981-06-18	1982-12-19	Astra Laekemedel Ab	Farmaceutisk mixtur
US4424235A (en)	1981-09-14	1984-01-03	Hoffmann-La Roche Inc.	Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
DE3447075A1 (de) *	1984-12-22	1986-07-03	Dr. Karl Thomae Gmbh, 7950 Biberach	Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arzneimittel
DE3572485D1 (en)	1984-12-22	1989-09-28	Thomae Gmbh Dr K	Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs
US4738851A (en)	1985-09-27	1988-04-19	University Of Iowa Research Foundation, Inc.	Controlled release ophthalmic gel formulation
US4709712A (en)	1986-10-22	1987-12-01	Dermatalogical Products Of Texas	Polycarboxylic acid polymer gels as protective agents
GB8828020D0 (en)	1988-12-01	1989-01-05	Unilever Plc	Topical composition
US5026559A (en)	1989-04-03	1991-06-25	Kinaform Technology, Inc.	Sustained-release pharmaceutical preparation
US5133974A (en)	1989-05-05	1992-07-28	Kv Pharmaceutical Company	Extended release pharmaceutical formulations
KR0167346B1 (ko)	1989-06-09	1999-01-15	로버트 에이. 아미테이지	중추신경계 활성을 갖는 헤테로사이클릭 아민
US5273975A (en)	1989-06-09	1993-12-28	The Upjohn Company	Heterocyclic amines having central nervous system activity
GB9015822D0 (en)	1990-07-18	1990-09-05	Beecham Group Plc	Compositions
US5472712A (en) *	1991-12-24	1995-12-05	Euroceltique, S.A.	Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5656296A (en) *	1992-04-29	1997-08-12	Warner-Lambert Company	Dual control sustained release drug delivery systems and methods for preparing same
US5431920A (en)	1993-09-21	1995-07-11	Merck Frosst, Canada, Inc.	Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5458887A (en) *	1994-03-02	1995-10-17	Andrx Pharmaceuticals, Inc.	Controlled release tablet formulation
WO1997004752A1 (fr) *	1995-07-26	1997-02-13	Duramed Pharmaceuticals, Inc.	Compositions pharmaceutiques d'oestrogenes conjugues et leurs modes d'emploi
WO1998055107A1 (fr)	1997-06-06	1998-12-10	Depomed, Inc.	Formes de dosage de medicaments administres par voie orale a retention gastrique pour liberation lente de medicaments hautement solubles
CA2290966C (fr)	1997-07-01	2005-12-20	Pfizer Inc.	Sels de sertraline et formes posologiques de sertraline, a liberation prolongee
US5895663A (en)	1997-07-31	1999-04-20	L. Perrigo Company	Pseudoephedrine hydrochloride extended-release tablets
CA2211778A1 (fr) *	1997-08-14	1999-02-14	Francois Carriere	Preparation d'un amidon riche en amylose pregelatinise et deramifie utile comme excipient pour la liberation prolongee de principes actifs
US7153845B2 (en)	1998-08-25	2006-12-26	Columbia Laboratories, Inc.	Bioadhesive progressive hydration tablets
US6624200B2 (en)	1998-08-25	2003-09-23	Columbia Laboratories, Inc.	Bioadhesive progressive hydration tablets
DE69819748T2 (de)	1997-09-12	2004-09-30	Columbia Laboratories (Bermuda) Ltd.	Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
US6248358B1 (en)	1998-08-25	2001-06-19	Columbia Laboratories, Inc.	Bioadhesive progressive hydration tablets and methods of making and using the same
US6197339B1 (en) *	1997-09-30	2001-03-06	Pharmacia & Upjohn Company	Sustained release tablet formulation to treat Parkinson's disease
US6056977A (en) *	1997-10-15	2000-05-02	Edward Mendell Co., Inc.	Once-a-day controlled release sulfonylurea formulation
GB9802201D0 (en) *	1998-02-03	1998-04-01	Cerestar Holding Bv	Free-flowable directly compressible starch as binder,disintegrant and filler for compresion tablets and hard gelatine capsules
JP2002506031A (ja)	1998-03-11	2002-02-26	スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー	組成物
GB9812426D0 (en)	1998-06-10	1998-08-05	Reckitt & Colmann Prod Ltd	Improvements in or relating to organic compositions
TW407058B (en)	1998-07-17	2000-10-01	Dev Center Biotechnology	Oral cisapride dosage forms with an extended duration
DE19906290A1 (de)	1999-02-15	2000-08-17	Falk Pharma Gmbh	Arzneimittel zur Behandlung bzw. Prävention von Darmkrebs
US7374779B2 (en)	1999-02-26	2008-05-20	Lipocine, Inc.	Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
EP1169024B1 (fr) *	1999-03-31	2005-12-21	Janssen Pharmaceutica N.V.	Amidon pregelatinise dans une formulation a liberation regulee
DE19927688A1 (de)	1999-06-17	2000-12-21	Gruenenthal Gmbh	Mehrschichttablette zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac
DE60022692T2 (de)	1999-07-01	2006-06-22	Pharmacia & Upjohn Co. Llc, Kalamazoo	(S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen
AP2002002410A0 (en)	1999-08-04	2002-03-31	Ranbaxy Laboratories Ltd	Hydrodynamically Balancing Oral Drug Delivery System
CO5210862A1 (es)	1999-09-15	2002-10-30	Alza Corp	Formas de dosificacion y metodos para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia
CA2384840A1 (fr)	1999-09-30	2001-04-05	The General Hospital Corporation	Utilisation de pramipexole pour traiter l'etat de besoin de cocaine
US20030180352A1 (en) *	1999-11-23	2003-09-25	Patel Mahesh V.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CN1434713A (zh) *	1999-12-22	2003-08-06	法马西亚公司	环加氧酶－2抑制剂的缓释制剂
US6467637B2 (en)	2000-01-27	2002-10-22	The York Group, Inc.	Death care merchandising system
PT1257277E (pt)	2000-02-24	2005-09-30	Pharmacia & Upjohn Co Llc	Novas combinacoes de farmacos
US6277875B1 (en) *	2000-07-17	2001-08-21	Andrew J. Holman	Use of dopamine D2/D3 receptor agonists to treat fibromyalgia
ES2187249B1 (es)	2000-09-18	2004-09-16	Synthon Bv	Procedimiento para la preparacion de 2-amino-6-(alquil)amino-4,5,6,7-tetrahidrobenzotiazoles.
SE0004671D0 (sv)	2000-12-15	2000-12-15	Amarin Dev Ab	Pharmaceutical formulation
DE10138275A1 (de)	2001-08-10	2003-02-27	Boehringer Ingelheim Pharma	Verbindungen zur Beseitigung der Anhedonie
CA2470636A1 (fr)	2001-12-20	2003-07-03	Pharmacia Corporation	Formes dosifiees a liberation soutenue d'ordre zero et procede de production associe
BR0312876A (pt)	2002-07-25	2005-06-28	Pharmacia Corp	Método de preparação de formas de dosagem sólidas revestidas em duas camadas compreendendo um polìmero insolúvel em água e um agente formador de poros solúvel em água
PA8578501A1 (es)	2002-07-25	2005-02-04	Pharmacia Corp	Forma de dosificacion una vez al dia de pramipexol
US20070196481A1 (en)	2002-07-25	2007-08-23	Amidon Gregory E	Sustained-release tablet composition
US20050226926A1 (en)	2002-07-25	2005-10-13	Pfizer Inc	Sustained-release tablet composition of pramipexole
US20040121010A1 (en)	2002-10-25	2004-06-24	Collegium Pharmaceutical, Inc.	Pulsatile release compositions of milnacipran
WO2004080440A1 (fr)	2003-03-11	2004-09-23	Korea United Pharm, Inc.	Procede servant a preparer une formulation en gelules dures contenant lansoprasole
MXPA05010636A (es)	2003-04-04	2005-12-12	Pharmacia Corp	Comprimidos de multiparticulas preparados por compresion de liberacion oral prolongada.
US20050020589A1 (en)	2003-06-18	2005-01-27	Pfizer Inc.	Sustained-release tablet composition comprising a dopamine receptor agonist
CN101022788B (zh)	2004-08-13	2010-11-10	贝林格尔·英格海姆国际有限公司	包含普拉克索或其可药用盐的延长释放小球制剂、其制备方法及其用途
UA93608C2 (ru)	2004-08-13	2011-02-25	Берингер Ингельхайм Интернациональ Гмбх	композициЯ таблетки пролонгированного высвобождения, которая содержит прамипексол или его фармацевтически приемлемую соль, СПОСОБ EE ИЗГОТОВЛЕНИЯ И EE ПРИМЕНЕНИЕ
WO2006046256A1 (fr)	2004-10-27	2006-05-04	Alembic Limited	Formulation a liberation prolongee de dihydrochlorure de pramipexole
WO2007002518A1 (fr)	2005-06-23	2007-01-04	Spherics, Inc.	Formes de dosage de pramipexole a liberation retardee ou a liberation prolongee/retardee
CA2613631A1 (fr)	2005-06-23	2007-01-04	Spherics, Inc.	Formes de dosage ameliorees pour le traitement de troubles moteurs
ATE444750T1 (de)	2005-08-15	2009-10-15	Univ Virginia	Neurorestauration mit r(+) pramipexol
WO2007054976A2 (fr)	2005-11-08	2007-05-18	Panacea Biotec Ltd.	Nouvelles compositions pharmaceutiques a liberation controlee a base de lipides
EP1988875A2 (fr)	2006-02-10	2008-11-12	Boehringer Ingelheim International GmbH	Formulation a liberation modifiee
WO2007090883A1 (fr)	2006-02-10	2007-08-16	Boehringer Ingelheim International Gmbh	Formulation à libération prolongée
WO2007090882A2 (fr)	2006-02-10	2007-08-16	Boehringer Ingelheim International Gmbh	Compositions pharmaceutiques
EP1886665A1 (fr)	2006-08-01	2008-02-13	Boehringer Ingelheim Pharma GmbH & Co. KG	Système thérapeutique gastro-retentif

2003
- 2003-07-23 US US10/626,166 patent/US20050226926A1/en not_active Abandoned
- 2003-07-24 AR AR20030102666A patent/AR040681A1/es unknown
- 2003-07-24 PA PA20038578301A patent/PA8578301A1/es unknown
- 2003-07-24 MY MYPI20032784A patent/MY138846A/en unknown
- 2003-07-24 PE PE2003000734A patent/PE20040130A1/es not_active Application Discontinuation
- 2003-07-25 DE DE60323235T patent/DE60323235D1/de not_active Expired - Lifetime
- 2003-07-25 PT PT03771807T patent/PT1531814E/pt unknown
- 2003-07-25 OA OA1200500016A patent/OA13303A/en unknown
- 2003-07-25 AP AP2005003205A patent/AP2201A/xx active
- 2003-07-25 AU AU2003261241A patent/AU2003261241B2/en not_active Ceased
- 2003-07-25 GE GEAP8599A patent/GEP20074048B/en unknown
- 2003-07-25 PL PL375696A patent/PL215587B1/pl unknown
- 2003-07-25 JP JP2004524787A patent/JP4700963B2/ja not_active Expired - Fee Related
- 2003-07-25 SI SI200331350T patent/SI1531814T1/sl unknown
- 2003-07-25 ME MEP-523/08A patent/MEP52308A/xx unknown
- 2003-07-25 CA CA002492854A patent/CA2492854C/fr not_active Expired - Fee Related
- 2003-07-25 TW TW092120406A patent/TWI347849B/zh not_active IP Right Cessation
- 2003-07-25 EP EP03771807A patent/EP1531814B1/fr not_active Expired - Lifetime
- 2003-07-25 ES ES03771807T patent/ES2310673T3/es not_active Expired - Lifetime
- 2003-07-25 EA EA200702187A patent/EA200702187A1/ru unknown
- 2003-07-25 MX MXPA05001054A patent/MXPA05001054A/es active IP Right Grant
- 2003-07-25 KR KR1020057001392A patent/KR100712832B1/ko not_active Expired - Fee Related
- 2003-07-25 NZ NZ537790A patent/NZ537790A/en unknown
- 2003-07-25 BR BR0312960-8A patent/BR0312960A/pt not_active IP Right Cessation
- 2003-07-25 CN CNB038178737A patent/CN1313092C/zh not_active Expired - Fee Related
- 2003-07-25 HR HRP20041235AA patent/HRP20041235B1/hr not_active IP Right Cessation
- 2003-07-25 EP EP08159203A patent/EP1987832A1/fr not_active Withdrawn
- 2003-07-25 WO PCT/US2003/023205 patent/WO2004010997A1/fr not_active Ceased
- 2003-07-25 DK DK03771807T patent/DK1531814T3/da active
- 2003-07-25 AT AT03771807T patent/ATE406162T1/de active
- 2003-07-25 RS YU20050059A patent/RS51719B/sr unknown
- 2003-07-25 EA EA200500079A patent/EA009663B1/ru not_active IP Right Cessation
- 2003-07-31 UY UY27912A patent/UY27912A1/es not_active Application Discontinuation
2004
- 2004-12-29 IS IS7623A patent/IS7623A/is unknown
- 2004-12-30 IL IL16607804A patent/IL166078A0/xx unknown
2005
- 2005-01-06 NO NO20050093A patent/NO334298B1/no not_active IP Right Cessation
- 2005-01-17 ZA ZA200500439A patent/ZA200500439B/xx unknown
- 2005-01-24 EC EC2005005568A patent/ECSP055568A/es unknown
- 2005-01-24 CR CR7661A patent/CR7661A/es unknown
- 2005-01-25 MA MA28066A patent/MA27328A1/fr unknown
- 2005-01-25 CU CU20050018A patent/CU23440B7/es not_active IP Right Cessation
2008
- 2008-10-13 CY CY20081101125T patent/CY1110408T1/el unknown
2010
- 2010-03-03 US US12/716,755 patent/US8399016B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
PA8578301A1 (es)	2004-07-20
MA27328A1 (fr)	2005-05-02
EP1531814B1 (fr)	2008-08-27
UY27912A1 (es)	2004-02-27
NZ537790A (en)	2005-10-28
ZA200500439B (en)	2006-08-30
NO20050093L (no)	2005-02-24
TWI347849B (en)	2011-09-01
AP2201A (en)	2011-01-24
HRP20041235A2 (en)	2005-06-30
EA200702187A1 (ru)	2008-06-30
EP1987832A1 (fr)	2008-11-05
JP4700963B2 (ja)	2011-06-15
CN1313092C (zh)	2007-05-02
DK1531814T3 (da)	2008-10-13
EA200500079A1 (ru)	2005-06-30
WO2004010997A8 (fr)	2005-02-24
PL375696A1 (en)	2005-12-12
SI1531814T1 (sl)	2008-12-31
US8399016B2 (en)	2013-03-19
ES2310673T3 (es)	2009-01-16
ATE406162T1 (de)	2008-09-15
RS20050059A (sr)	2007-08-03
MEP52308A (en)	2011-02-10
AU2003261241B2 (en)	2009-06-18
MY138846A (en)	2009-07-31
ECSP055568A (es)	2005-04-18
RS51719B (sr)	2011-10-31
EP1531814A1 (fr)	2005-05-25
CR7661A (es)	2005-06-08
JP2005538106A (ja)	2005-12-15
IS7623A (is)	2004-12-29
CA2492854C (fr)	2009-10-20
US20050226926A1 (en)	2005-10-13
BR0312960A (pt)	2005-06-14
CY1110408T1 (el)	2015-04-29
HK10777456A1 (en)	2007-11-30
AP2005003205A0 (en)	2005-03-31
PE20040130A1 (es)	2004-03-06
MXPA05001054A (es)	2005-04-08
KR100712832B1 (ko)	2007-04-30
AU2003261241A1 (en)	2004-02-16
AR040681A1 (es)	2005-04-13
DE60323235D1 (de)	2008-10-09
PL215587B1 (pl)	2013-12-31
TW200418523A (en)	2004-10-01
PT1531814E (pt)	2008-10-29
WO2004010997A1 (fr)	2004-02-05
EA009663B1 (ru)	2008-02-28
KR20050062516A (ko)	2005-06-23
IL166078A0 (en)	2006-01-15
US20100316710A1 (en)	2010-12-16
GEP20074048B (en)	2007-02-26
CU23440B7 (es)	2009-10-16
CN1671382A (zh)	2005-09-21
NO334298B1 (no)	2014-01-27
CA2492854A1 (fr)	2004-02-05
HRP20041235B1 (hr)	2013-07-31

Publication	Publication Date	Title
CA2492854C (fr)	2009-10-20	Composition de comprime a liberation prolongee de pramipexole
AU2003256921B2 (en)	2009-03-05	Pramipexole once-daily dosage form
HK1078007B (en)	2011-01-14	Pramipexole once-daily dosage form